ASP49-phospholipase A2-loaded liposomes as experimental therapy in cutaneous leishmaniasis model

Barros, Neuza Biguinati de; Macedo, Sharon Rose Aragão; Ferreira, Amália S.; Tagliari, Monika Piazzon; Kayano, Anderson M.; Nicolete, Larissa D.F.; Soares, Andreimar M.; Nicolete, Roberto

doi:10.1016/j.intimp.2017.12.012

Cited by 16 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been previously shown that PLA 2 activates NF-kB in isolated peritoneal macrophages ( Moreira et al, 2014 ). Additionally, treatment with liposome encapsulated PLA 2 isolated from the venom of Bothrops jararacussu , resulted in a significant rise in TNF-α and NO production in the cutaneous lesions as well as lymph nodes of L. amazonensis -infected BALB/c mice ( de Barros et al, 2018 ).…”

Section: Host-targeted Therapeutics and Approaches For Treatment Of Lmentioning

confidence: 99%

Host-Directed Drug Therapies for Neglected Tropical Diseases Caused by Protozoan Parasites

et al. 2018

View full text Add to dashboard Cite

The neglected tropical diseases (NTDs) caused by protozoan parasites are responsible for significant morbidity and mortality worldwide. Current treatments using anti-parasitic drugs are toxic and prolonged with poor patient compliance. In addition, emergence of drug-resistant parasites is increasing worldwide. Hence, there is a need for safer and better therapeutics for these infections. Host-directed therapy using drugs that target host pathways required for pathogen survival or its clearance is a promising approach for treating infections. This review will give a summary of the current status and advances of host-targeted therapies for treating NTDs caused by protozoa.

show abstract

Section: Host-targeted Therapeutics and Approaches For Treatment Of Lmentioning

confidence: 99%

Host-Directed Drug Therapies for Neglected Tropical Diseases Caused by Protozoan Parasites

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Another way is to utilize a special delivery system for a toxin to reduce its general toxic effect. So, a PLA2 from B. jararacussu venom encapsulated in liposomes displays therapeutic effectiveness comparable to that of known antiparasitic Glucantime in a cutaneous leishmaniasis mouse model [ 70 ]. A fairly original construct has been developed based on the expression of a PLA2 from the B. pauloensis venom in a leishmanial “suicidal” strain, which leads to the inducible death of the parasite cells in vitro [ 71 ].…”

Section: Discussionmentioning

confidence: 99%

The Potassium Channel Blocker β-Bungarotoxin from the Krait Bungarus multicinctus Venom Manifests Antiprotozoal Activity

et al. 2023

View full text Add to dashboard Cite

Protozoal infections are a world-wide problem. The toxicity and somewhat low effectiveness of the existing drugs require the search for new ways of protozoa suppression. Snake venom contains structurally diverse components manifesting antiprotozoal activity; for example, those in cobra venom are cytotoxins. In this work, we aimed to characterize a novel antiprotozoal component(s) in the Bungarus multicinctus krait venom using the ciliate Tetrahymena pyriformis as a model organism. To determine the toxicity of the substances under study, surviving ciliates were registered automatically by an original BioLaT-3.2 instrument. The krait venom was separated by three-step liquid chromatography and the toxicity of the obtained fractions against T. pyriformis was analyzed. As a result, 21 kDa protein toxic to Tetrahymena as isolated and its amino acid sequence was determined by MALDI TOF MS and high-resolution mass spectrometry. It was found that antiprotozoal activity was manifested by β-bungarotoxin (β-Bgt) differing from the known toxins by two amino acid residues. Inactivation of β-Bgt phospholipolytic activity with p-bromophenacyl bromide did not change its antiprotozoal activity. Thus, this is the first demonstration of the antiprotozoal activity of β-Bgt, which is shown to be independent of its phospholipolytic activity.

show abstract

“…The phospholipase A2 (PPA2)-derived peptides are enzymes commonly present in the venom of organisms from all kingdoms, belonging to natural origin, and can hydrolyze phospholipids from cell membranes. Short peptides derived from PPA2 can cross the membrane showing effective activity against Leishmania promastigotes and amastigotes [98,99]. Interestingly, these cationic peptides, rich in lysines, increase their affinity when the lysines are substituted with arginines [100].…”

Section: Amps and Cpps For Combatting Different Forms Of Leishmaniosismentioning

confidence: 99%

Neglected Zoonotic Diseases: Advances in the Development of Cell-Penetrating and Antimicrobial Peptides against Leishmaniosis and Chagas

Robledo,

Pérez-Silanes,

Fernández-Rubio

et al. 2023

Preprint

View full text Add to dashboard Cite

In 2020, the WHO established a road map for neglected tropical diseases 2021−2030 that aims to control and eradicate 20 diseases, including Leishmaniosis and Chagas disease. In addition, since 2015, the WHO has been developing a Global Action Plan on Antimicrobial Resistance. In this context, the achievement of innovative strategies as an alternative to replace conventional therapies is a first-order socio-sanitary priority, especially regarding endemic zoonoses in poor regions such as those caused by Trypanosoma cruzi and Leishmania spp infections. In this scenario, it is worth highlighting a group of natural peptide molecules (AMPs and CPPs) that are promising strategies for improving therapeutic efficacy against these neglected zoonoses, avoiding the development of toxicity and resistance of conventional treatments. This review presents the novelties of these peptide molecules and their ability to cross a whole system of cell membranes, as well as to stimulate the host immune defenses or even serve as a vector of molecules. The efforts of the biotechnological sector will make it possible to overcome the limitations of antimicrobial peptides through encapsulation and functionalization methods to obtain approval for these treatments to be used in clinical programs for the eradication of Leishmaniosis and Chagas disease.

show abstract

ASP49-phospholipase A2-loaded liposomes as experimental therapy in cutaneous leishmaniasis model

Cited by 16 publications

References 18 publications

Host-Directed Drug Therapies for Neglected Tropical Diseases Caused by Protozoan Parasites

Host-Directed Drug Therapies for Neglected Tropical Diseases Caused by Protozoan Parasites

The Potassium Channel Blocker β-Bungarotoxin from the Krait Bungarus multicinctus Venom Manifests Antiprotozoal Activity

Neglected Zoonotic Diseases: Advances in the Development of Cell-Penetrating and Antimicrobial Peptides against Leishmaniosis and Chagas

Contact Info

Product

Resources

About